Amylyx Pharmaceuticals, Inc.’s announcement that the US Food & Drug Administration is re-convening the Peripheral & CNS Drugs Advisory Committee for another look at the proposed ALS therapy AMX0035 has plenty of people struggling to think of a precedent for FDA to bring an NDA to an advisory committee twice during the same review cycle. (Also see "Will Amylyx’s ALS Drug Benefit From US FDA’s Aduhelm Experience?" - Pink Sheet, 5 July, 2022.)
There is no shortage of examples of the same application going to an advisory committee more than once. It is...





